Target intelligence / Profile preview

Mitosis machinery (collective mitotic apparatus) (null)

Target
null
Molecular classification
Other (multi-component molecular machine), Contains: Enzymes (e.g., kinases, topoisomerase IIα), Structural proteins (e.g., tubulin, actin, SMC proteins), Motor proteins (e.g., kinesins, dyneins), Regulatory factors (e.g., Ect2, TPX2, NuMA, RanGTP)
01

Overview

The **mitosis machinery** refers to all molecular assemblies required for faithful segregation of duplicated genetic material and cytoskeletal components during cell division. This includes the mitotic spindle (assembled from microtubules and regulated by proteins like kinesin-5, dynein, and spindle assembly factors such as TPX2, NuMA, RanGTP), chromosomal scaffold proteins (condensin complex, topoisomerase IIα), and kinases (CDK1, Aurora kinases) that orchestrate the dynamic reorganization of cytoskeletal and chromosomal structures. The machinery ensures proper alignment, segregation, and division of chromosomes and cell contents, and defects in its function can lead to aneuploidy, cancer, developmental disorders, and cell death[1][4][6][7]. Many anti-cancer drugs target components of this machinery, but its multi-component nature means "mitosis machinery" itself is not a single drug target, and any therapeutic intervention must selectively target one or more of its molecular parts.

Other names
Mitotic machinerymitotic apparatuscell division machinerymitotic spindle machinery
02

Mechanism of action

Inhibition of microtubule polymerization/depolymerization (causing mitotic arrest); Inhibition of kinase activity (e.g., Aurora kinases, CDKs block cell cycle progression); Inhibition of topoisomerase II (block chromatid separation)

03

Biological functions

Cell cycle progressionChromosome segregationSpindle assembly/organizationCytokinesisCell proliferationCell division
04

Disease associations

Cancer (errors in mitosis machinery contribute to aneuploidy and tumorigenesis)Neurodegenerative disease (mitotic dysfunction implicated in pathogenesis)Other (developmental disorders, some genetic diseases)
05

Safety considerations

Myelosuppression (neutropenia)Neurotoxicity (for microtubule drugs)Secondary malignancies (possible with topoisomerase II inhibitors)Mucosal toxicity, alopecia, GI toxicity (class-specific side effects)
06

Interacting drugs

Microtubule inhibitors: Taxanes (paclitaxel, docetaxel)

4 more in the full profile.

07

Biomarkers

Mitotic indexPhosphorylation status of CDK1, Aurora kinasesExpression levels of mitotic proteins (e.g., Ki-67, cyclins)

Beyond the preview

Go deeper on Mitosis machinery (collective mitotic apparatus) (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitosis machinery (collective mitotic apparatus) (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call